Nuvisan, based in Waltrop, Germany, will use ERS'w Genomics CRISPR-Cas9 portfolio to help advance its clients' drug discovery and early development programs.
The company is commercializing a test that combines genetic and hormone data with a woman's medical history to make personalized birth control recommendations.
